Nitric oxide, but not vasodilating prostaglandins, contributes to the improvement of exercise hyperemia via ascorbic acid in healthy older adults.
Acute ascorbic acid (AA) administration increases muscle blood flow during dynamic exercise in older adults, and this is associated with improved endothelium-dependent vasodilation. We directly tested the hypothesis that increase in muscle blood flow during AA administration is mediated via endothelium-derived vasodilators nitric oxide (NO) and prostaglandins (PGs). In 14 healthy older adults (64 ± 3 yr), we measured forearm blood flow (FBF; Doppler ultrasound) during rhythmic handgrip exercise at 10% maximum voluntary contraction. After 5-min steady-state exercise with saline, AA was infused via brachial artery catheter for 10 min during continued exercise, and this increased FBF ∼25% from 132 ± 16 to 165 ± 20 ml/min (P < 0.05). AA was infused for the remainder of the study. Next, subjects performed a 15-min exercise bout in which AA + saline was infused for 5 min, followed by 5 min of the nitric oxide synthase (NOS) inhibitor N(G)-monomethyl-l-arginine (l-NMMA) and then 5 min of the cyclooxygenase inhibitor ketorolac (group 1). The order of inhibition was reversed in eight subjects (group 2). In group 1, independent NOS inhibition reduced steady-state FBF by ∼20% (P < 0.05), and subsequent PG inhibition had no impact on FBF (Δ 3 ± 5%). Similarly, in group 2, independent PG inhibition had little effect on FBF (Δ -4 ± 4%), whereas subsequent NO inhibition significantly decreased FBF by ∼20% (P < 0.05). In a subgroup of five subjects, we inhibited NO and PG synthesis before AA administration. In these subjects, there was a minimal nonsignificant improvement in FBF with AA infusion (Δ 7 ± 3%; P = nonsignificant vs. zero). Together, our data indicate that the increase in muscle blood flow during dynamic exercise with acute AA administration in older adults is mediated primarily via an increase in the bioavailability of NO derived from the NOS pathway.
Crecelius
Anne R
AR
Department of Health and Exercise Science, Colorado State University, Fort Collins, Colorado 80523-1582, USA.
Kirby
Brett S
BS
Voyles
Wyatt F
WF
Dinenno
Frank A
FA
D000368:Aged; D000375:Aging / Q000502:physiology; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D015444:Exercise / Q000502:physiology*; D005260:Female; D005542:Forearm / Q000098:blood supply; D018737:Hand Strength / Q000502:physiology; D006801:Humans; D006940:Hyperemia / Q000188:drug therapy* / Q000378:metabolism* / Q000503:physiopathology; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011453:Prostaglandins / Q000378:metabolism*; D012039:Regional Blood Flow / Q000187:drug effects; D013997:Time Factors; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology*
D000975:Antioxidants; D011453:Prostaglandins; D009569:Nitric Oxide; D001205:Ascorbic Acid
Ann N Y Acad Sci. 2004 Dec;1031:425-7
15753187
Circulation. 1996 Mar 15;93(6):1107-13
8653830
Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):697-705
16424350
Circ Res. 1998 Nov 2;83(9):916-22
9797340
Annu Rev Med. 1997;48:489-509
9046979
Hypertension. 1997 Mar;29(3):736-43
9052889
J Physiol. 2002 Sep 1;543(Pt 2):691-8
12205200
Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1963-70
18310521
Hypertension. 2009 Jun;53(6):993-9
19433775
Hypertension. 2001 Aug;38(2):274-9
11509489
J Physiol. 2005 Nov 1;568(Pt 3):1057-65
16141271
Am J Physiol Heart Circ Physiol. 2003 Sep;285(3):H1023-31
12738622
J Biol Chem. 2001 Jan 5;276(1):40-7
11022034
J Physiol. 2009 May 1;587(Pt 9):1989-2003
19307300
Biochem Biophys Res Commun. 1975 Mar 17;63(2):463-8
235924
J Physiol. 2007 Feb 15;579(Pt 1):227-36
17138603
Exerc Sport Sci Rev. 1991;19:313-49
1936089
J Physiol. 1994 Oct 15;480 ( Pt 2):361-8
7869251
Microcirculation. 2006 Jun;13(4):315-27
16611597
J Physiol. 2004 Apr 1;556(Pt 1):315-24
14754992
Am J Physiol Regul Integr Comp Physiol. 2006 Sep;291(3):R803-9
16556903
Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2576-84
15271659
Circulation. 2000 Jun 27;101(25):2896-901
10869260
J Appl Physiol (1985). 2003 Nov;95(5):1963-70
12882993
J Physiol. 2001 Feb 15;531(Pt 1):257-64
11179408
J Cardiovasc Pharmacol. 1996;27 Suppl 2:S9-12
8723393
J Physiol. 2003 Nov 15;553(Pt 1):281-92
12949223
J Physiol. 2004 Jun 1;557(Pt 2):599-611
15047770
Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1870-5
19767527
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12814-9
11606734
J Physiol. 2008 Feb 15;586(4):1161-8
18063659
Hypertension. 2009 Jun;53(6):973-8
19414649
Am J Physiol Heart Circ Physiol. 2003 Apr;284(4):H1251-9
12595287
Lancet. 1989 Oct 28;2(8670):997-1000
2572793
Acta Physiol Scand. 1998 Mar;162(3):421-36
9578388
J Physiol. 2007 Jun 1;581(Pt 2):853-61
17347273